GSK 2881078
Alternative Names: GSK-2881078Latest Information Update: 27 Jul 2022
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cachexia
Most Recent Events
- 27 Jul 2022 No development reported - Phase-II for Cachexia (In the elderly, In adults) in United Kingdom, Germany (PO) (NDR Batch 2022)
- 19 Nov 2019 GlaxoSmithKline completes a phase II trial in Cachexia (In the elderly, In adults) in USA, United Kingdom, Germany (PO) (NCT03359473)
- 28 Feb 2018 Phase-II clinical trials in Cachexia (In adults, In the elderly) in USA (PO) (NCT03359473)